Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

NCT07415005 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Lorlatinib

Sponsor

M.D. Anderson Cancer Center